CVRX News and Press, CVRx Inc. From 06/21/22

CVRx's Barostim is a long-term compounder that presents with interesting economics. Clinical data is robust for the device and it continues to benefit from regulatory tailwinds. News around the device has been well priced into the stock, however, as investors price in growing syst...

MINNEAPOLIS, May 23, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the manage...

The shares of Humacyte (NASDAQ:HUMA) are trading sharply lower on Monday after Piper Sandler downgraded the clinical-stage biotech to Underweight from Overweight expecting weakness in the near-term and citing attractiveness in the commercial-stage companies. The analysts led by Matt O'Brien c...

CVRx (NASDAQ:CVRX) said it received U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR) conditional labeling for its Barostim heart failure system. The Minneapolis-based company said the Barostim system now includes instructions to allow for safe MRI scans of the head...

Heart failure patients implanted with Barostim can now receive conditional MRI scans MINNEAPOLIS, May 09, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the ...

CVRx, Inc. (CVRX) Q1 2022 Earnings Conference Call April 25, 2022 4:30 PM ET Company Participants Mike Vallie - Westwicke, ICR Company Nadim Yared - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Matthew O'...

CVRx press release (NASDAQ:CVRX): Q1 GAAP EPS of -$0.49 in-line. Revenue of $4.08M (+42.7% Y/Y) beats by $0.29M. For further details see: CVRx GAAP EPS of -$0.49 in-line, revenue of $4.08M beats by $0.29M

MINNEAPOLIS, April 25, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announce...

MINNEAPOLIS, April 12, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans...

Gainers: CRISPR Therapeutics AG (NASDAQ:CRSP) +26%. Micron Technology, Inc. (NASDAQ:MU) +15%. CVRx, Inc. (NASDAQ:CVRX) +11%. Academy Sports and Outdoors, Inc. (NASDAQ:ASO) +8%. KLX Energy Services Holdings, Inc. (NASDAQ:KLXE) +6%. Losers: Gilat Satellite Networks Ltd. (NASDAQ:G...